Clinical Trials Browser

INDUSTRY × Sarcoma, Synovial × Cyclophosphamide × Clear all

Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT07174427 2026-02-18

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

Phase 3 Recruiting

5 enrolled

Sarcoma

Sarcoma, Synovial

NCT05492682 2025-09-05

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Phase 1 Active not recruiting

15 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT03250325 2024-11-20

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Phase 1/2 Completed

8 enrolled

Sarcoma

Sarcoma, Synovial

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2 Withdrawn

Sarcoma

Neoplasms, Sarcoma, Synovial

Clinical Trials

IGNYTE-ESO

Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a